KMT2A and leukemia: The mice bearing 20–30% GFP+ MLL-AF9 leukemia were treated with 3 MBq/21 μg of Lu-IF7 mAb, unlabelled IF7 mAb, IIIA4 anti-EphA3 mAb [14] (Lu-IIIA4) control (as MLL-AF9 leukemia do not express EphA3) or PBS control.